Overview

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

Status:
Terminated

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

The main objectives of this study are to establish a safe, tolerable and active dose of 1018 ISS administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer. Other objectives also include determining tumor response, time to disease progression, and overall survival in treated patients.

Phase:

Phase 1

Details

Lead Sponsor:

Dynavax Technologies Corporation

Treatments:

1018 oligonucleotide
Cetuximab
Irinotecan